<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383705</url>
  </required_header>
  <id_info>
    <org_study_id>DHF24491</org_study_id>
    <nct_id>NCT03383705</nct_id>
  </id_info>
  <brief_title>VBeam Prima for Treatment of Photoaged Facial Skin</brief_title>
  <official_title>VBeam Prima for Treatment of Photoaged Facial Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-center study. Subjects in this study will receive up to four
      (4) facial treatments at 4-6 (±1) weeks interval, with the VBeam Prima device according to
      the study protocol. Subjects will return for follow‐up (FU) visits at the clinic at 1 and 3
      months following the last treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">November 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Improvement Scale</measure>
    <time_frame>1 or 3 months post last treatment</time_frame>
    <description>Overall improvement using Global Improvement Scale (0=no response; 4=excellent response).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wrinkle and Elastosis Score</measure>
    <time_frame>Pre Tx.4, 1 month and 3 months post final treatment</time_frame>
    <description>Improvement using Fitzpatrick Wrinkle Class and Elastosis Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment discomfort based on NRS Scale</measure>
    <time_frame>Immediately post treatment</time_frame>
    <description>Evaluate treatment discomfort based on NRS Scale as reported by study subjects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Photoaged Facial Skin</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VBeam Prima</intervention_name>
    <description>Up to four treatments will be performed every 4-6 (±1) weeks.</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Male or Female at least 18 years of age

          2. Photoaged facial skin with clinically visible background erythema, telangiectasia, or
             pigmented lesions

          3. Fitzpatrick Elastosis Score 2-9

          4. Fitzpatrick Skin Type I - VI

          5. Able to read, understand and sign the Informed Consent Form

          6. Willing and able to adhere to the treatment and follow-up schedule and post-treatment
             care instructions

          7. Willing to have limited sun exposure for the duration of the study, including the
             follow-up period

          8. Willing to have photographs taken of the treated area which will be used,
             de-identified, in evaluations and may be used, de-identified, in presentations and/or
             publications

          9. For female candidates - subject must be post-menopausal, or surgically sterilized, or
             using a medically acceptable form of birth control during the entire course of the
             study.

        Exclusion Criteria:

          1. Pregnant or planning to become pregnant during the study duration.

          2. Implant in the treated area (such as metal plates or screws) or an injected chemical
             substance.

          3. Known collagen (connective tissue) disorder, vascular disease (i.e. saphenous reflux),
             scleroderma or other autoimmune disease (i.e. rheumatoid arthritis, lupus).

          4. History of diseases stimulated by heat or sun exposure, such as recurrent Herpes
             Simplex in the treated area, unless treatment is conducted following a prophylactic
             regimen.

          5. History of immunosuppression/immune deficiency disorders (including HIV infection or
             AIDS) or currently using immunosuppressive medications.

          6. Undergoing any form of treatment for active cancer, or having a history of skin cancer
             or any other cancer in the areas to be treated, including actinic keratosis, presence
             of malignant or pre-malignant pigmented lesions.

          7. Significant concurrent illness, such as such as cardiac disorders, diabetes (type I or
             II), or pertinent neurological disorders.

          8. Infection or are suffering from a current or a history of significant skin conditions
             in the treated area and/or inflammatory skin conditions, including, but not limited
             to: photodermatoses, psoriasis, eczema, rash, severe open wound stage rosacea, open
             cuts or scrapes and active cold sores or herpes sores prior to study treatment or
             during the study treatment course.

          9. Anticoagulative or thromboembolic condition or taking anticoagulation medications one
             week prior to and during the treatment course (to allow inclusion, temporary cessation
             of use might be requested as per the subject's physician discretion).

         10. Use of aspirin or pain relievers from the ibuprofen family (e.g., Motrin®, Advil®, or
             Naprosyn®) on a regular basis or would be taking any of these pain relievers one week
             before and after each study treatment session.

         11. History of keloid scarring or of abnormal wound healing.

         12. Photosensitivity to the device's laser wavelengths, history of ingesting medications
             known to induce photosensitivity, or history of seizure disorders due to light.

         13. Surgical, light-based therapy or RF procedures in the treatment area within 3 months
             of treatment or during the study.

         14. Any other surgery in the treated area within 3 months of treatment (or more if skin
             has not healed completely) or during the study.

         15. Tattoo or permanent make-up in the treated area.

         16. Systemica use of retinoids (i.e. Retin-A®, Accutane®) or antioxidants (i.e.
             Restylane®, Strivectin®) within 2 months of study treatment or during the study.

         17. Excessive tan in areas to be treated or unable/unlikely to refrain from tanning during
             the study.

         18. Participation in a study of another device or drug within three months prior to
             enrollment or during the study.

         19. As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gilly Munavalli, MD</last_name>
    <phone>(704) 375-6766</phone>
    <email>info@carolinaskin.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy Tucker, RN-C</last_name>
    <phone>(704) 375-6766</phone>
    <email>info@carolinaskin.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dermatology, Laser &amp; Vein Specialists of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Tucker, RN-C</last_name>
      <phone>704-375-6766</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Photoaged Skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

